Legend Biotech says CARVYKTI posts about $710 million net trade sales in quarter ended Sept. 30, 2026

LEGN•2026-10-13

Legend Biotech flagged preliminary CARVYKTI net trade sales of about $710 million for the quarter ended Sept. 30, 2026. Partner Janssen provided the figure, which Legend Biotech has not independently verified.

1. Preliminary sales figure

Legend Biotech flagged preliminary CARVYKTI net trade sales of about $710 million for the quarter ended Sept. 30, 2026. Janssen provided the figure, which Legend Biotech has not independently verified; the update disclosed no percentage changes.

Sources

Legend Biotech says CARVYKTI posts about $710 million net trade sales in quarter ended Sept. 30, 2026

Sec

Legend Biotech says CARVYKTI posts about $710 million net trade sales in quarter ended Sept. 30, 2026

1. Preliminary sales figure

Related News

Canaccord Genuity initiates coverage of Seaport Therapeutics with buy rating, $28 price target

Nasdaq pauses TCRT trading for volatility at 9:40 a.m.

Jaguar Health reports positive preliminary crofelemer study results in adult short bowel syndrome patients with intestinal failure

Sources

Legend Biotech says CARVYKTI posts about $710 million net trade sales in quarter ended Sept. 30, 2026

AeroVironment executive urges Australia to pursue “operational sovereignty” via allied integration under AUKUS

Quad study finds 75% of Americans see simpler tech use as lifestyle upgrade